Session 1: Cancer -I

摘要

Fully human antibodies are rapidly becoming the norm in antibody therapy. Genmab has a number of clinical programs in cancer including antibodies against CD4, CD20 and CD38. This presentation will address the selection of highly potent therapeutic antibodies against lymphoid tumors. Insights into the mechanisms of action and recent data from clinical development will be discussed.